Roluperidone
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A receptor, 5-HT2A and sigma-2 receptor, σ2 receptor receptor antagonist, antagonist under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity (pharmacology), affinity for the histamine H1 receptor, H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on brain-derived neurotrophic factor ("BDNF"), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. As of May 2018, the drug was in Phases of clinical research#Phase III, phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements." However, in August 2022 Minerva submitted a New Drug ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]